1620 Investment Advisors’s Pacira BioSciences PCRX Stock Holding History

1620 Investment Advisors’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$21.2K	Sell	834 -143	-15%	-$3.38K	0.01%	415
2026 Q1	$22.1K	Hold	977	–	–	0.01%	386
2025 Q4	$25.3K	Hold	977	–	–	0.02%	370
2025 Q3	$25.2K	Hold	977	–	–	0.02%	363
2025 Q2	$23.4K	Sell	977 -15	-2%	-$378	0.02%	380
2025 Q1	$24.7K	Hold	992	–	–	0.02%	364
2024 Q4	$18.7K	Sell	992 -35	-3%	-$615	0.01%	397
2024 Q3	$15.5K	Buy	1,027 +439	+75%	+$7.51K	0.01%	433
2024 Q2	$16.8K	Buy	+588	New	+$16.7K	0.01%	416

Other funds holding PCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DPCM

Doma Perpetual Capital Management Miami, Florida $431M AUM 13.21% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

1620 Investment Advisors's PCRX Position: Q2 2026 in Review

1620 Investment Advisors reduced its Pacira BioSciences (PCRX) stake by 15% in Q2 2026, selling an estimated $3.38K and leaving 834 shares worth $21.2K. The position accounts for 0.01% of the portfolio, ranked #415.

1620 Investment Advisors first reported a position in PCRX in Q2 2024 and has held it in 9 quarters since. The position peaked at $25.3K in Q4 2025. 254 funds tracked by Wall St. Rank hold PCRX as of Q2 2026.

1620 Investment Advisors held 834 shares of Pacira BioSciences worth $21.2K as of Q2 2026.
1620 Investment Advisors sold 143 Pacira BioSciences shares in Q2 2026, an estimated $3.38K.
Pacira BioSciences made up 0.01% of 1620 Investment Advisors's portfolio in Q2 2026, its #415 holding.
1620 Investment Advisors first reported a position in Pacira BioSciences in Q2 2024 and has held it in 9 quarters since.
1620 Investment Advisors's Pacira BioSciences position peaked at $25.3K in Q4 2025.
254 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2026.

Based on 1620 Investment Advisors's 13F filing for Q2 2026, filed 14 Jul 2026.